Physician profile
Farhan A Sheikh
NPI 1265551873
$12,432.43
in general payments reported to CMS, 2019-2025
62 companies · $1,784 in 2025
The $1,784 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,453 · 2020: $1,270 · 2021: $1,909 · 2022: $2,580 · 2023: $1,317 · 2024: $2,119 · 2025: $1,784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,220.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,307.49 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Abbvie INC. | $1,153.64 | 2019-2025 | Duopa, Ubrelvy, Qulipta |
| Teva Pharmaceuticals USA, INC. | $925.52 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Neurocrine Biosciences, INC. | $653.02 | 2019-2025 | Ingrezza, Ongentys |
| Biogen, INC. | $562.07 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Emd Serono, INC. | $498.84 | 2019-2025 | Mavenclad |
| Mdd US Operations, LLC | $419.85 | 2020-2025 | Apokyn, Gocovri, Apokyn |
| Sk Life Science, INC. | $399.95 | 2020-2025 | |
| Eisai INC. | $353.91 | 2019-2025 | |
| Amgen INC. | $340.00 | 2019-2025 | Otezla, Repatha |
| Lundbeck LLC | $290.57 | 2019-2025 | Vyepti, Rexulti |
| Abbott Laboratories | $274.36 | 2021-2025 | Infinity |
| Amneal Pharmaceuticals LLC | $258.65 | 2019-2025 | Crexont, Rytary |
| Adamas Pharmaceuticals, INC. | $252.42 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $247.32 | 2019-2025 | Nuplazid |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $235.96 | 2021-2025 | Zeposia |
| Jazz Pharmaceuticals INC. | $233.39 | 2019-2025 | |
| Genzyme Corporation | $231.13 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $227.52 | 2019-2023 | Ultomiris |
| Avion Pharmaceuticals | $217.31 | 2022-2023 | Dhivy |
| Argenx US, INC. | $212.04 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Supernus Pharmaceuticals, INC. | $197.23 | 2019-2025 | Qelbree |
| Genentech USA, INC. | $195.15 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Kyowa Kirin, INC. | $188.12 | 2022-2025 | Nourianz |
| Upsher-Smith Laboratories LLC | $185.31 | 2020-2022 | |
| Nevro Corp. | $180.74 | 2024 | Senza |
| Novartis Pharmaceuticals Corporation | $171.69 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $158.20 | 2021 | |
| Lilly USA, LLC | $158.05 | 2019-2025 | Kisunla, Amyvid |
| Janssen Pharmaceuticals, INC | $136.46 | 2020-2022 | |
| Pfizer INC. | $133.77 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $116.53 | 2022 | |
| Acorda Therapeutics, INC | $114.96 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $108.40 | 2023-2025 | Rexulti |
| Neurelis, INC. | $104.01 | 2021-2023 | Valtoco |
| Allergan, INC. | $88.94 | 2019-2020 | |
| Livanova USA, INC. | $82.35 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Axsome Therapeutics, INC. | $68.83 | 2024-2025 | Symbravo, Sunosi |
| Novo Nordisk INC | $62.07 | 2023-2025 | Wegovy |
| Aucta Pharmaceuticals, INC. | $56.48 | 2024-2025 | Motpoly Xr |
| Catalyst Pharmaceuticals, INC. | $55.65 | 2022-2024 | Fycompa |
| Harmony Biosciences LLC | $46.36 | 2023-2024 | Wakix |
| Sumitomo Pharma America, INC. | $46.23 | 2024 | Aptiom |
| Cycle Pharmaceuticals INC | $42.29 | 2025 | Tascenso Odt, Bafiertam |
| Corium, LLC | $39.67 | 2022-2023 | Adlarity |
| Ani Pharmaceuticals, INC. | $38.37 | 2025 | Purified Cortrophin Gel |
| Avanir Pharmaceuticals, INC. | $37.39 | 2019 | |
| Mallinckrodt Hospital Products INC. | $36.32 | 2022-2024 | Acthar |
| Grifols USA, LLC | $32.96 | 2025 | Prolastin-C Liquid |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.41 | 2025 | Caplyta |
| Zyla Life Sciences, INC. | $28.55 | 2019 | |
| Azurity Pharmaceuticals, INC. | $23.70 | 2025 | Horizant |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.95 | 2025 | Lifevest |
| Xeris Pharmaceuticals, INC. | $22.50 | 2023 | Keveyis |
| Astrazeneca Pharmaceuticals LP | $21.11 | 2025 | Fasenra |
| Glaxosmithkline, LLC. | $21.10 | 2025 | Trelegy Ellipta |
| Aprecia Pharmaceuticals, LLC | $15.79 | 2020 | |
| Ge Healthcare | $15.16 | 2019 | |
| Exact Sciences Corporation | $14.04 | 2023 | Cologuard Collection Kit |
| Electronic Waveform Lab, INC. | $13.40 | 2019 | |
| Mallinckrodt Enterprises LLC | $13.21 | 2019 | |
| Nestle Healthcare Nutrition INC. | $13.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farhan Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.